The Research Of Hypoxia-inducible Factor-1? In Ulcerative Colitis

Part ? Role of hypoxia inducible factor-1? in pathogenesis and disease evaluation of ulcerative colitisObjective The randomized controlled trial was used to detect the content of hypoxia inducible factor-1? in serum and intestinal tissue of patients with ulcerative colitis and prospectively evaluate its correlation with disease activity, clinical severity and endoscopic grading.Methods A total of 47 active ulcerative colitis patients and 13 ulcerative colitis in remission patients were recruited for the present study. Ten healthy subjects were also included to serve as controls. HIF? 1? in the serum was measured using enzyme linked immunosorbent assay (ELISA).The citrate? microwave? SP immunohistochemical method was used to measure the expression of HIF? 1? in colonic mucosa.Results The results showed that, HIF? 1? in serum was notably higher in active ulcerative colitis patients (73.21±28.65 ng/L) than ulcerative colitis in remission patients (44.54±14.75 ng/L) and controls (42.83±15.49 ng/L). The difference between active ulcerative colitis patients and ulcerative colitis in remission patients and controls was significant (P<0.05), but no difference between ulcerative colitis in remission patients and controls (P>0.05). A correlation analysis revealed that, patients in the remission group, no correlation between serum HIF-1? levels and Mayo score (r=0.139, P>0.05), in the active group of patients, there was a significant correlation between the serum levels of HIF-1? and Mayo score (r=0.699, P<0.01), the levels of serum HIF-1? in active ulcerative colitis patients with clinical condition performance and endoscopic grading was showed a significant positive correlation (r=0.696, r=0.674 P<0.01), the HIF? 1? level in serum was positively associated with disease activity, disease severity and endoscopic grade. The expression of HIF? 1? in colonic mucosa of active ulcerative colitis patients was (58.05±13.83%) higher than that in ulcerative colitis in remission patients (3.00±2.72%) and controls (3.04±2.69%) and this difference was statistically significant (P<0.05), but no difference between ulcerative colitis in remission patients (3.00±2.72%)and controls (3.04±2.69%) (P>0.05). In the remission group, no correlation between the rate of colonic mucosa HIF-1a positive expression and Mayo score(r=0.108, P>0.05), in the active group of ulcerative colitis patients, colonic mucosa HIF-1? expression was significantly correlated with Mayo score (r=0.743, P<0.01). A positive correlation was identified between the expression of HIF? 1? in colonic mucosa and the disease activity, severity and endoscopic grade(r=0.699, r=0.677, P<0.01).Conclusion The present findings indicated that, HIF? 1? is likely to play an important role in the pathogenesis of UC and may serve as a biomarker to evaluate disease activity and severity in UC patients.Part ? Detection and significance of serum hypoxia inducible factor-1? and CRP with ulcerative colitis patientsObjective To detect the serum hypoxia inducible factor-1 alpha (HIF-1?) and CRP of patients with ulcerative colitis, and to investigate its relationship with disease activity and severity.Methods In the early morning, when awake, fasting venous blood was each selected 4ml for ulcerative colitis patients,3000 rpm centrifuge for 10 minutes, the serum and red blood cells were separated quickly and carefully. Samples were collected and stored in -70?, enzyme-linked immunosorbent assay (ELISA) was performed to detect the serum levels of HIF-1?, the experiment was carried out according to the kit instructions, and the result was to calculate the concentration of each sample. CRP content was detected by immune transmission turbidity method after senting blood samples immediately to the Department of inspection. The active ulcerative colitis patients underwent the checking of colonoscopy and the evaluation of disease severity.Results The expression of HIF-1? in serum was significantly higher in active ulcerative colitis patients than those in remission and control group (P<0.05), and no significant difference between remission and control group (P>0.05), the level of CRP in serum was significantly higher in active ulcerative colitis patients than those in remission and control group (P<0.05), and no significant difference between remission and control group (P>0.05); A correlation analysis revealed that, patients in the remission group, no correlation between serum HIF-la levels and Mayo score (r=0.139, P>0.05), in the active group of patients, there was a significant correlation between the serum levels of HIF-la and Mayo score (r=0.699, P<0.01), the levels of serum HIF-la in active ulcerative colitis patients with clinical condition performance and endoscopic grading was showed a significant positive correlation (r=0.696, r=0.674 P<0.01). In the remission group, there was no correlation between the serum CRP and Mayo score (r=0.097, P>0.05), in the active group of patients, the serum CRP and Mayo score was significantly correlated (r=0.715, P<0.05), the level of serum CRP in patients with active ulcerative colitis was moderate positively correlated with the clinical classification and endoscopic grading (r=0.554, r=0.562, P<0.001). and there was a positive correlation between HIF-la and CRP(r=0.881, P<0.01).Conclusion HIF-la as a transcription factor may play an important role in the pathogenesis of ulcerative colitis, and combined detection of HIF-la and CRP can be used as good indexs to evaluate disease activity and severity in patients with UC.